5 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 5, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion Relacorilant - Type 2 Diabetes, Hypercortisolism | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 34 | 2026-12-01 | 2026-11-09 |
| Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate [18F]CETO tracer, Dexamethasone oral, Adrenal vein sampling - Primary Aldosteronism | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 12 | 2024-11-06 | 2025-01-27 |
| Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism Al18F-NOTA-Pentixafor PET/CT - Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 150 | 2023-12-30 | 2025-02-26 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants Dabigatran Etexilate, Relacorilant - Cushing Syndrome, Neoplasms | Phase 1 | Completed | Corcept Therapeutics | 30 | 2022-05-25 | 2023-02-09 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism Brain MRI - Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism | Phase 1 | Unknown | National Taiwan University Hospital | 60 | 2019-01-25 | 2019-01-30 |
| Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia Subcutaneous hydrocortisone - Congenital Adrenal Hyperplasia, Hyperplasia | Phase 1 | Completed | University of Minnesota | 11 | 2019-01-01 | 2025-06-25 |
| Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia NBI-77860 - Congenital Adrenal Hyperplasia | Phase 1 | Withdrawn | Neurocrine Biosciences | 2015-02-01 | 2015-06-11 | |
| Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults Mifepristone, Placebo - Endocrine Disease, Diabetes | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 19 | 2011-11-29 | 2021-04-14 |
Cushing Syndrome (5) · Adrenal Gland Diseases (3) · Endocrine System Diseases (3) · Hyperaldosteronism (3) · ACTH Syndrome, Ectopic (2) · Adrenal Hyperplasia, Congenital (2) · Diabetes Mellitus, Type 2 (2) · Disorders of Sex Development (2) · Genetic Diseases, Inborn (2) · Glucose Intolerance (2) · Hyperplasia (2) · Hypertension (2) · Pathologic Processes (2) · Steroid Metabolism, Inborn Errors (2)
Adrenal Gland Diseases (7) · Endocrine System Diseases (7) · Nutritional and Metabolic Diseases (5) · Metabolic Diseases (4) · Glucose Metabolism Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (2) · Diabetes Mellitus (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Paraneoplastic Endocrine Syndromes (2) · Paraneoplastic Syndromes (2)
relacorilant (3) · Dabigatran (1) · Dexamethasone (1) · Mifepristone (1) · NBI 77860 (1) · pembrolizumab (1)
Corcept Therapeutics (2) · Crinetics Pharmaceuticals Inc. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · National Taiwan University Hospital (1) · Neurocrine Biosciences (1) · Peking Union Medical College Hospital (1) · The University of Texas Health Science Center at San Antonio (1) · University Medical Center Groningen (1) · University of Minnesota (1)
United States (7) · China (1) · Netherlands (1) · Taiwan (1)
Andreas G Moraitis, MD (1) · Dr. M.N. Kerstens (1) · Hsin-Hsi Tsai, MD (1) · Joseph Custodio, PhD (1) · Kyriaki Sarafoglou, MD (1) · Lynnette K Nieman, M.D. (1) · Ralph DeFronzo, MD (1)
PMID 33278125, PMID 33507248, PMID 33859526, PMID 36074157
2023 (1), ZIADK075121 (1)